Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DryEye

Financiado

Cerrado

Validation of a Novel Diagnostic Biomarker for Dry Eye Syndrome based in nucleot...

Validation of a Novel Diagnostic Biomarker for Dry Eye Syndrome based in nucleotides detection Scientists of our company invented a method for diagnosing and monitoring the effectiveness of dry-eye syndrome treatment. The invention is related to a method for diagnosing the Dry Eye syndrome in patients and monitoring the eff... ver más

31/01/2016

OCUPHARM

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

OCUPHARM DIAGNOSTICS SL No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-01-31

PHC-12-2014-1: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

OCUPHARM

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

eyePoC Clinical validation of a new diagnostic and monitoring PoC m... 71K€ Cerrado

DI-15-07639 Diagnóstico Molecular del Síndrome de Ojo Seco 65K€ Cerrado

IPT-2012-0438-010000 Soluciones innovadoras para el tratamiento y diagnostico del... 648K€ Cerrado

PID2019-111139RB-I00 LIPIDOMICA DE LA LAGRIMA EN LA PATOLOGIA DE OJO SECO: POTENC... 145K€ Cerrado

PTQ-08-01-06626 Desarrollo de un dispositivo diagnostico diferencial para Oj... 94K€ Cerrado

PTQ-08-01-06630 Desarrollo de un dispositivo diagnostico diferencial para Oj... 37K€ Cerrado

Duración del proyecto: 8 meses Fecha Inicio: 2015-05-04
Fecha Fin: 2016-01-31

Líder del proyecto

OCUPHARM DIAGNOSTICS SL No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Scientists of our company invented a method for diagnosing and monitoring the effectiveness of dry-eye syndrome treatment. The invention is related to a method for diagnosing the Dry Eye syndrome in patients and monitoring the effectiveness of the treatment, by measuring the concentration of a molecule called diadenosine tetraphosphate dinucleotide (Ap4A). Ap4A is an intracellular signal molecule that is produced due to harsh environmental factors. According to our studies published since 2002, Ap4A is released from the corneal epithelium, stimulating tear production and is a physiological modulator of tear secretion. Most importantly we discovered that levels of Ap4A are up to 5 times above normal levels in patients with Dry Eye compared to patients with normal lacrimation. This increase is even higher in Dry Eye individuals with low tear production. In these cases the Ap4A is increased over 100 fold. Following this discovery we patented a method to measure the concentrations of Ap4A of tear samples from patients in order to determine its presence, which is abnormally high in the case of Dry Eye syndrome. According to this method it is possible objectively to confirm or to discount the presence of this pathology. The diagnostic method of this invention comprises: detection by means of the high-pressure liquid chromatography (HPLC) technique of the Ap4A molecule, for the purposes of the calculation of which use will be made of a standard sample of Ap4A of commercial origin and of known concentration; and the use of a luminometric method for the detection and quantification of the Ap4A dinucleotide by means of the use of luciferin luciferase. We already effectively tested the method in vitro and in vivo on Dry Eye animal models. Recently we made a successful first stage trial in a small number of patients. Our future actions include the collaboration with industry partners, expert on biomarkers, in order to create a small detection kit.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores